Oncocyte Starts FDA Submissions Process for Kidney Transplant Monitoring Test

Precision diagnostics company, Oncocyte Corporation (Nasdaq: OCX), has initiated the FDA single-site process for its VitaGraft kidney transplant assays. This process is a well-established pathway for Lab Developed Tests (LDT) to seek regulatory approval. VitaGraft Kidney is a non-invasive, blood-based transplant monitoring test that assesses organ health and rejection risk status, post-transplantation. There is a…